Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Tennessee: - T C Thompson Children's Hospital — Chattanooga, Tennessee
- East Tennessee Childrens Hospital — Knoxville, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Tennessee: - Tennessee Oncology Nashville St Thomas Midtown Clinic — Nashville, Tennessee
- Tennessee Oncology — Nashville, Tennessee
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Tennessee: - Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga — Chattanooga, Tennessee
- Tennessee Oncology — Nashville, Tennessee
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Tennessee: - Sarah Cannon Research Institute SCRI — Nashville, Tennessee
Phase 2, Phase 3 Recruiting Industry
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07634471
Sites in Tennessee: - SCRI Oncology Partners ( Site 7000) — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Tennessee: - Tennessee Oncology - Nashville / Sarah Cannon Research Institute — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Tennessee: - The Children's Hospital at TriStar Centennial — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Tennessee: - TriStar Centennial Medical Center — Nashville, Tennessee
Phase 2 Recruiting Industry
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-H…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06806033
Sites in Tennessee: - Tennessee Oncology — Chattanooga, Tennessee
- Tennessee Oncology — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Tennessee: - Tennesse Oncology Chattanooga Downtown — Chattanooga, Tennessee
- Tennessee Oncology, Pllc Nashville — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Tennessee: - University of Tennessee Medical Center — Knoxville, Tennessee
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Tennessee: - The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Sponsor: Kite, A Gilead Company
NCT ID: NCT04989803
Sites in Tennessee: - Tennessee Oncology, PLLC - Investigational Drug Services — Nashville, Tennessee
- Vanderbilt University — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate t…
Sponsor: Cellectis S.A.
NCT ID: NCT04150497
Sites in Tennessee: - Sarah Cannon - HCA Research Institute — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumu…
Sponsor: Indapta Therapeutics, INC.
NCT ID: NCT06119685
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.
Sponsor: T. John Winhusen, PhD
NCT ID: NCT06651177
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Sponsor: AstraZeneca
NCT ID: NCT07109219
Sites in Tennessee: - Research Site — Franklin, Tennessee
Phase 2 Recruiting Academic/Other
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refracto…
Sponsor: City of Hope Medical Center
NCT ID: NCT04561206
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or m…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06390319
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unr…
Sponsor: Recursion Pharmaceuticals Inc.
NCT ID: NCT06678659
Sites in Tennessee: - SCRI Oncology Partners - PPDS — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Sponsor: TORL Biotherapeutics, LLC
NCT ID: NCT07439653
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee